Form 4: Tharimmune, Inc. COO Receives Stock Options

Sireesh Appajosyula, Chief Operating Officer of Tharimmune, Inc., was granted options to purchase 52,875 shares of common stock on January 13, 2025.

Summary

• Sireesh Appajosyula, the Chief Operating Officer of Tharimmune, Inc., received options to purchase 52,875 shares of the company's common stock on January 13, 2025.
• The options were granted pursuant to the company's 2023 Omnibus Equity Incentive Plan.
• The exercise price of the options is $1.93.
• The options vested fully upon grant and expire on January 13, 2035.
• Following the transaction, Appajosyula directly owns 115,962 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a common practice and suggests confidence in the executive's ability to contribute to the company's success. There are no immediately negative implications.

Positives

• The grant of stock options to the COO aligns his interests with those of the shareholders.
• The vesting of the options upon grant suggests confidence in the COO's ability to contribute to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their executives.
• The size of the grant is typical for a COO role in a company of Tharimmune's size and stage of development.

Key Dates

Keywords

Tharimmune, stock options, Form 4, COO, Sireesh Appajosyula, equity incentive plan